Interview: Andrejs Pantelejevs – Head of Bureau, Ministry of Health, Latvia

20.03.2018
Andrejs Pantelejevs, head of bureau of the Ministry of Health of Latvia, discusses the importance of channeling the recent EUR 200 million healthcare financing to raising the wages of practitioners, reimbursing expensive innovative medicines in therapeutic areas such as oncology and cardiovascular diseases as well as strengthening e-health. Can you please introduce yourself and your role as Head of Bureau of the Ministry of Health?
"In general, the Latvian pharmaceutical market is very small and often, given its size, is not very easy to negotiate prices."
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Baltics, Latvia, MoH, Healtchare, Reimbursement, E-Health

Related Interviews

Interview: Vasily Bankovsky – Chairman of the Board & Founder; Svetlana…

Vasily and Svetlana Bankovsky, founders of Biosan, talk about the company’s philosophy to develop modern, exciting personal products for sample preparation in the field of genomics, proteomics and cellomics and…

Interview: Anda Čakša – Minister of Health, Latvia

Anda Čakša, Latvia’s minister of health since 2016, discusses her current priorities, regulatory reform, areas of strengths and weaknesses in the nation’s healthcare infrastructure, e-health, and combating the threat of…

Interview: Inese Bolmane – Business Development Manager, Cilmes Šūnu…

Inese Bolmane, business development manager at Latvian stem cell bank Cilmes Šūnu Banka, explains the basic rationale behind stem cell banking and what differentiates Cilmes Šūnu Banka from the competition.…

Related Articles

A Pivot Towards Recruitment Process Outsourcing (RPO) in the Baltics

As the Lithuanian market matures, profound shifts have been taking place in the arena of human resources and how drug developers go about identifying, acquiring and retaining the personnel they…

Diabetes in Lithuania: A Silent Crisis

With over 120,000 people whose lives are affected by the disease in Lithuania; diabetes stands as one of the country’s major health issues today. Furthermore, as Marijus Valatka, general manager…

Lithuania’s Biotech Potential

Lithuania’s biotech sector has grown by between 20 and 25 percent over the last five years and accounts for over one percent of the entire country’s GDP. Key industry stakeholders…

Latest Report

Denmark Pharma Report 2021

Related Content

Baltics
Latvia
MoH
Healtchare
Reimbursement
E-Health